Data Year:

For its 2024 fiscal year, REGENXBIO Inc., listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Kenneth T. Mills
Former President and CEO, Director
Total Compensation $5,507,038 View details Pay Rank By Title In Biotechnology industry #2 View more
Curran Simpson
President and CEO
Total Compensation $4,784,544 View details Pay Rank By Title In Biotechnology industry #273 View more
Olivier Danos Ph.D.
EVP, Chief Scientific Officer
Total Compensation $2,956,949 View details Pay Rank By Title In Biotechnology industry #81 View more
Patrick J. Christmas
EVP, Chief Strategy and Legal Officer
Total Compensation $2,737,813 View details Pay Rank By Title In Biotechnology industry #91 View more
Vit Vasista
Former EVP, Chief Financial Officer
Total Compensation $2,226,951 View details Pay Rank By Title In Biotechnology industry #217 View more
Stephen Pakola M.D.
EVP, Chief Medical Officer
Total Compensation $2,696,859 View details Pay Rank By Title In Biotechnology industry #93 View more
Mitchell Chan
EVP, Chief Financial Officer
Total Compensation $3,205,294 View details Pay Rank By Title In Biotechnology industry #140 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at REGENXBIO Inc. as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. REGENXBIO Inc. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. REGENXBIO Inc. annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Kenneth T. Mills
Former President and CEO, Director
Total Cash $747,072 Equity $4,665,243 Other $94,723 $5,507,038
Curran Simpson
President and CEO
Total Cash $861,412 Equity $3,903,294 Other $19,838 $4,784,544
Olivier Danos Ph.D.
EVP, Chief Scientific Officer
Total Cash $728,675 Equity $2,186,825 Other $41,449 $2,956,949
Patrick J. Christmas
EVP, Chief Strategy and Legal Officer
Total Cash $703,720 Equity $2,014,255 Other $19,838 $2,737,813
Vit Vasista
Former EVP, Chief Financial Officer
Total Cash $507,710 Equity $1,166,315 Other $552,926 $2,226,951
Stephen Pakola M.D.
EVP, Chief Medical Officer
Total Cash $730,496 Equity $1,946,525 Other $19,838 $2,696,859
Mitchell Chan
EVP, Chief Financial Officer
Total Cash $198,267 Equity $2,999,983 Other $7,044 $3,205,294
For its 2024 fiscal year, REGENXBIO Inc., listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Curran Simpson CEO Pay $3,495,826 Median Employee Pay $226,641 CEO Pay Ratio 15:1
For its 2024 fiscal year, REGENXBIO Inc., listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
A.N. "Jerry" Karabelas, Ph.D. Total Cash $339,981
Alexandra Glucksmann, Ph.D. Total Cash $327,481
Allan M. Fox Total Cash $337,481
Daniel Tassé Total Cash $347,481
David C. Stump, M.D. Total Cash $339,981
George Migausky Total Cash $339,981
Jean Bennett, M.D., Ph.D. Total Cash $324,981
Jennifer Zachary Total Cash $329,981
Kenneth T. Mills Total Cash $40,000
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.